Genomic Valley Biotech Limited Open Offer Seeks 26% at ₹30

Genomic Valley Biotech Limited is subject to a mandatory open offer for up to 7,94,170 shares, or 26% of its voting capital, at ₹30 per share, with a maximum consideration of ₹2.38 crore. The offer follows an agreement by Pankaj Grover and Abhisek Gupta to acquire a 46.06% promoter stake for ₹4.22 crore.

Why is Genomic Valley Biotech facing an open offer?

Genomic Valley Biotech is facing the open offer because Pankaj Grover and Abhisek Gupta agreed to acquire a controlling 46.06% stake from promoter Yogesh Agrawal. The acquirers signed the share purchase agreement on October 19, 2026, to buy 14,07,000 equity shares at ₹30 per share. The total consideration for that transaction is ₹4.22 crore.

The acquisition triggered a mandatory offer to public shareholders under Regulation 3(1) and Regulation 4 of the Securities and Exchange Board of India, or SEBI, Substantial Acquisition of Shares and Takeovers Regulations, 2011. These regulations require an acquirer crossing specified ownership or control thresholds to provide other shareholders an opportunity to sell shares at the offer price.

Yogesh Agrawal's holding is expected to fall to nil following the underlying share purchase agreement. The disclosed shareholding split after that agreement gives Pankaj Grover a 29.69% holding and Abhisek Gupta a 16.37% holding. The subsequent open offer gives public shareholders a separate route to tender shares to the acquirers.

What are the terms and timetable of the ₹30 offer?

The offer is for up to 7,94,170 equity shares, representing 26.00% of Genomic Valley Biotech's voting equity share capital, at ₹30 per share in cash. If fully accepted, the maximum open-offer consideration will be ₹2.38 crore. There is no minimum acceptance condition, meaning the offer is not conditional on receiving a specified number of shares.

The tendering period is scheduled to open on December 14, 2026, and close on December 28, 2026. The acquirers may revise the offer until December 10, 2026, according to the disclosed timetable. The offer is described as non-conditional and not a competing offer.

Fintellectual Corporate Advisors Private Limited is acting as manager to the offer. The detailed public statement was published on October 27, 2026, in Financial Express, Jansatta and Mumbai Lakshadeep. A draft letter of offer was filed on November 3, 2026.

How will shareholders tender shares in the offer?

Eligible public shareholders can tender shares into the offer, subject to the conditions stated in the offer documents and applicable regulations. A shareholder may tender shares within the open-offer limit, but tendered shares cannot be withdrawn once submitted under the stated terms.

Shareholders must provide applicable approvals where required. The disclosures specifically note that non-resident shareholders need Reserve Bank of India clearance where applicable. Tendering investors must also comply with SEBI requirements and the procedures set out by the manager to the offer.

The offer is payable in cash at ₹30 per equity share. Since it has no minimum acceptance condition, completion does not depend on a threshold level of participation by public shareholders. Acceptance, however, remains subject to the tendering process and the conditions specified in the final offer documentation.

How is the offer funded and what does it mean for ownership?

The acquirers have arranged funds for the transaction through an escrow account with ₹60 lakh deposited, as disclosed in the draft letter of offer. The open offer itself has a maximum financial obligation of ₹2.38 crore, while the separate promoter-share purchase agreement is valued at ₹4.22 crore.

Assuming full acceptance of the open offer, the acquirers' disclosed post-offer holding would be 22,01,170 equity shares. This figure combines the 14,07,000 shares under the promoter agreement and the maximum 7,94,170 shares proposed to be acquired through the open offer. The transaction therefore provides for a substantial shift in ownership from the existing promoter to the two acquirers.

For investors, the key disclosed reference point is the ₹30 per-share cash offer. The documents do not set a minimum acceptance threshold or identify statutory approvals required for the offer itself at this stage, although individual shareholders may need approvals based on their residency status and holdings.

Why does the SEBI takeover process matter to investors?

The SEBI takeover framework is intended to ensure that public shareholders receive an exit opportunity when a company undergoes a substantial acquisition or a potential change in control. In this case, the 46.06% promoter stake agreement was the event that triggered the mandatory offer for 26% of voting capital.

The sequence of disclosures gives shareholders defined dates for reviewing the offer and deciding whether to tender. The public announcement was disclosed on October 19, 2026, the detailed public statement was published on October 27, and the draft letter of offer was filed on November 3. The formal tender window is scheduled for December 14 to December 28.

The transaction is relevant to Genomic Valley Biotech's public float and ownership structure because the acquirers may increase their stake beyond the promoter shares if shareholders accept the offer. The offer documents, timetable and tender conditions are the primary disclosures investors can use to assess the transaction.

Conclusion

Genomic Valley Biotech's ₹30-per-share open offer is linked directly to the proposed acquisition of 46.06% of the company from promoter Yogesh Agrawal. The offer covers up to 7,94,170 shares, or 26% of voting capital, and has a maximum value of ₹2.38 crore. It is a cash offer with no minimum acceptance condition.

Shareholders will next need to track any revision made by the December 10, 2026 deadline and the tender window from December 14 to December 28, 2026. They should also review the final offer documentation and ensure that any required approvals, including RBI clearance for eligible non-resident holders, are in place before tendering shares.